As the government shutdown becomes the longest on record, most offices, including the Food and Drug Administration, are below operating capacity. This, of course, directly affects the health care sector. It has understandably been hampering new drug efforts, leading to the FDA to not accept product applications or user fees for 2019.
Based on a news release from Aimmune, for example, the FDA has halted reviews on all applications submitted after December 21. On January 16th, though, Amgen (AMGN) went through a review with an FDA Advisory Committee and won an